CORE--IMAGING AND DOSIMETRY

核心A成像和剂量测定，将为该计划提供4个支持战神 项目 其中包括（1）提供动物和临床成像， (2)使用ADAPT II和SAAM进行抗体药代动力学建模 软件，（3）估计吸收的辐射剂量，和（4）计数 放射性测定的质量保证。 图像提供疾病指南 范围、扩散和手术治疗。 此外，他们是主要的 输入到患者的器官和肿瘤摄取的估计中。 需要建模，因为我们需要在-111单克隆抗体的生物分布， 替代后续的Y-90 Mab;因此，我们使用图像数据作为 建模者的输入来预测治疗应用的生物分布， 患者 我们将比较器官和肿瘤摄取的模型预测 手术样本 辐射剂量估计使用模型的 单个器官摄取时间-活性积分。 这种剂量估计将 与临床数据如血细胞水平进行比较。 最后， 计数实验质量保证将从核心A确定。 的 成像和剂量学核心将继续为王博士提供支持， 博士吴和夏夫利医生 此外，我们将继续密切 与Raubitschek博士1）以及Maryon博士的关系。 此外，本发明还 该核心将为动物提供成像和剂量估计服务 问题研究 将继续与AAPM第7工作组进行外部合作， 田纳西州橡树岭的RIDIC中心（Mike Stabin）。

Core A Imaging and Dosimetry, will provide 4 support ares to the Program Project. These include (1) the provision of animal and clinical imaging, (2) modeling of antibody pharmacokinetics using ADAPT II and SAAM software, (3) estimation of absorbed radiation doses, and (4) counting quality assurance in radioassays. Images provide a guide to disease extent, spread and surgical treatment. In addition, they are the primary input into the estimation of organ and tumor uptake in the patient. Modeling is needed since we require biodistributions of in-111 Mabs to stand in for the subsequent Y-90 Mab; thus, we use the image data as the modeler's input to predict the therapy application's biodistribution in patients. We will compare model predictions of organ and tumor uptake with surgical samples. Radiation dose is estimated using the model's individual organ uptake time-activity integrals. Such dose estimates will be compared with clinical data such as blood cell levels. Finally, counting experiment quality assurance will be determined from Core A. The Imaging and Dosimetry core will continue to provide support to Dr. Wong, Dr. Wu and Dr. Shively. In addition, we will maintain our close association with Dr. Raubitschek 1) as well as Dr. Maryon. Additionally, this Core will provide imaging and dose estimation service for the animal studies. External collaborations will continue with AAPM Task Group 7 and the RIDIC center at Oak Ridge TN (Mike Stabin).